Chemotherapy of advanced breast cancer: outcome and prognostic factors (Q35977908)

11 August 2017

Chemotherapy of advanced breast cancer: outcome and prognostic factors (English)

1 reference

11 August 2017

1 reference

4

Twelves CJ

1 reference

11 August 2017

Gregory WM

1

1 reference

11 August 2017

Smith P

2

1 reference

11 August 2017

Richards MA

3

1 reference

11 August 2017

Knight RK

5

1 reference

11 August 2017

Rubens RD

6

1 reference

11 August 2017

language of work or name

English

0 references

publication date

1 November 1993

1 reference

British Journal of Cancer

11 August 2017

1 reference

11 August 2017

68

1 reference

11 August 2017

5

1 reference

11 August 2017

988-995

1 reference

Chemotherapy and survival in advanced breast cancer: the inclusion of doxorubicin in Cooper type regimens

11 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1968749

A comparison of intermittent vs. continuous and of adriamycin vs. methotrexate 5-drug chemotherapy for advanced breast cancer A Cancer and Leukemia Group B study

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1968749

Weekly epirubicin for breast cancer with liver metastases and abnormal liver biochemistry

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1968749

Attitudes to chemotherapy: comparing views of patients with cancer with those of doctors, nurses, and general public

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1968749

A randomized comparison of single-agent doxorubicin and epirubicin as first-line cytotoxic therapy in advanced breast cancer

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1968749

Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. analysis and examples

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1968749

Adriamycin versus methotrexate in five-drug combination chemotherapy for advanced breast cancer. A randomized trial

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1968749

Combined cytotoxic and progestogen therapy for advanced breast cancer

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1968749

High-dose epirubicin as primary chemotherapy in advanced breast carcinoma: a phase II study

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1968749

Factors predicting for response, time to treatment failure, and survival in women with metastatic breast cancer treated with DAVTH: a prospective Eastern Cooperative Oncology Group study.

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1968749

Doxorubicin in advanced breast cancer: influence of schedule on response, survival and quality of life

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1968749

Assessment of response to therapy in advanced breast cancer (an amendment)

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1968749

Prognostic factors in metastatic breast cancer treated with combination chemotherapy

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1968749

Improving the quality of life during chemotherapy for advanced breast cancer. A comparison of intermittent and continuous treatment strategies.

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1968749

The influence of adjuvant chemotherapy on outcome after relapse for patients with breast cancer

24 September 2018

1 reference

12 December 2020

A comparison of subjective responses in a trial comparing endocrine with cytotoxic treatment in advanced carcinoma of the breast

1 reference

12 December 2020

Adriamycin alone or combined with vincristine in the treatment of advanced breast cancer

1 reference

12 December 2020

Adriamycin and mitomycin C as initial chemotherapy for advanced breast cancer

1 reference

12 December 2020

Mitoxantrone in advanced breast cancer--a phase II study with special attention to cardiotoxicity

1 reference

12 December 2020

Mitomycin C and vinblastine in the treatment of advanced breast cancer

1 reference

12 December 2020

Chemohormonal therapy in advanced carcinoma of the breast: Cancer and Leukemia Group B protocol 8081

1 reference

12 December 2020

"Classical" CMF versus a 3-weekly intravenous CMF schedule in postmenopausal patients with advanced breast cancer. An EORTC Breast Cancer Co-operative Group Phase III Trial (10808)

1 reference

12 December 2020

Epirubicin in breast cancer patients with liver metastases and abnormal liver biochemistry: Initial weekly treatment followed by rescheduling and intensification

1 reference

12 December 2020

Identifiers

DOI

10.1038/BJC.1993.467

1 reference

11 August 2017

1 reference

11 August 2017

PubMed publication ID

8217615

1 reference